{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-083046","form_type":"8-K","ticker":"KURA","cik":"0001422143","company_name":"Kura Oncology, Inc.","filed_at":"2025-06-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.249075+00:00","generated_at":"2026-05-19T18:15:42.317315+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Stockholders approve Amended 2014 Plan adding 4.75M shares; annual meeting results","bullets":["Stockholders approved Amended 2014 Equity Incentive Plan, increasing authorized shares by 4,750,000.","Elected Helen Collins, M.D., Thomas Malley, and Carol Schafer as Class II directors until 2028.","Ratified Ernst & Young as independent auditor for fiscal year ending December 31, 2025.","Advisory vote on executive compensation approved with 63,155,796 for, 1,522,754 against."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-083046","json":"https://secwatch.observer/filing/0000950170-25-083046.json","markdown":"https://secwatch.observer/filing/0000950170-25-083046.md","text":"https://secwatch.observer/filing/0000950170-25-083046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422143/000095017025083046/0000950170-25-083046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422143/000095017025083046/kura-20250605.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T18:15:42.317315+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}